Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
ADVANCED ENZYME TECHNOLOGIES TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ADVANCED ENZYME TECHNOLOGIES Mar-23 |
TEVA PHARMA Dec-13 |
ADVANCED ENZYME TECHNOLOGIES/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 328 | 3,483 | - | |
Low | Rs | 225 | 3,026 | - | |
Sales per share (Unadj.) | Rs | 48.3 | 1,998.8 | - | |
Earnings per share (Unadj.) | Rs | 9.3 | 124.9 | - | |
Cash flow per share (Unadj.) | Rs | 12.4 | 286.4 | - | |
Dividends per share (Unadj.) | Rs | 5.00 | 109.31 | - | |
Avg Dividend yield | % | 1.8 | 3.4 | 53.8% | |
Book value per share (Unadj.) | Rs | 110.5 | 2,220.3 | - | |
Shares outstanding (eoy) | m | 111.82 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 5.7 | 1.6 | 351.5% | |
Avg P/E ratio | x | 29.8 | 26.1 | 114.3% | |
P/CF ratio (eoy) | x | 22.3 | 11.4 | 196.1% | |
Price / Book Value ratio | x | 2.5 | 1.5 | 170.9% | |
Dividend payout | % | 53.8 | 87.5 | 61.5% | |
Avg Mkt Cap | Rs m | 30,939 | 2,759,528 | 1.1% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 1,148 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,712.8 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,355.9 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 5,406 | 1,695,000 | 0.3% | |
Other income | Rs m | 255 | 0 | - | |
Total revenues | Rs m | 5,661 | 1,695,000 | 0.3% | |
Gross profit | Rs m | 1,534 | 464,177 | 0.3% | |
Depreciation | Rs m | 350 | 137,008 | 0.3% | |
Interest | Rs m | 35 | 33,293 | 0.1% | |
Profit before tax | Rs m | 1,404 | 293,876 | 0.5% | |
Minority Interest | Rs m | 0 | 1,335 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -192,913 | -0.0% | |
Tax | Rs m | 365 | -3,588 | -10.2% | |
Profit after tax | Rs m | 1,039 | 105,885 | 1.0% | |
Gross profit margin | % | 28.4 | 27.4 | 103.6% | |
Effective tax rate | % | 26.0 | -1.2 | -2,130.8% | |
Net profit margin | % | 19.2 | 6.2 | 307.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 7,221 | 1,144,797 | 0.6% | |
Current liabilities | Rs m | 776 | 998,360 | 0.1% | |
Net working cap to sales | % | 119.2 | 8.6 | 1,380.0% | |
Current ratio | x | 9.3 | 1.1 | 811.9% | |
Inventory Days | Days | 255 | 91 | 280.6% | |
Debtors Days | Days | 68 | 96 | 70.6% | |
Net fixed assets | Rs m | 6,884 | 553,624 | 1.2% | |
Share capital | Rs m | 224 | 4,172 | 5.4% | |
Net worth | Rs m | 12,351 | 1,882,824 | 0.7% | |
Long term debt | Rs m | 78 | 866,691 | 0.0% | |
Total assets | Rs m | 14,105 | 3,873,619 | 0.4% | |
Interest coverage | x | 41.4 | 9.8 | 420.9% | |
Debt to equity ratio | x | 0 | 0.5 | 1.4% | |
Sales to assets ratio | x | 0.4 | 0.4 | 87.6% | |
Return on assets | % | 7.6 | 3.6 | 211.8% | |
Return on equity | % | 8.4 | 5.6 | 149.5% | |
Return on capital | % | 11.6 | 4.9 | 234.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,404 | 270,095 | 0.5% | |
From Investments | Rs m | -2,982 | -95,706 | 3.1% | |
From Financial Activity | Rs m | -258 | -323,998 | 0.1% | |
Net Cashflow | Rs m | -1,709 | -149,608 | 1.1% |
Compare ADVANCED ENZYME TECHNOLOGIES With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare ADVANCED ENZYME TECHNOLOGIES With: VINEET LABORATORIES SHILPA MEDICARE NEULAND LABS SUVEN PHARMACEUTICALS ALPA LAB
After opening the day on positive note, Indian share markets reversed the trend as the session progressed and ended lower.